Skip to main
  1. Stocks
  2. AxoGen
  3. Forecast
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is favored fundamentally because 3Q26 showed strong, broad-based demand, with revenue of $75.8 million up 26.2% year over year, gross margin of 74.8%, and net income of $2.3 million, signaling improving operating leverage and a path toward sustainable profitability. Management’s raised FY2026 outlook to at least $290 million in revenue, at least 73% gross margin, and positive free cash flow, supported by Avance coverage near 96% of covered lives, a larger sales force, and breast revenue growing more than 50% to over 60% in 3Q26. The October 1, 2026 BioCircuit acquisition and NerveTape broaden the product set, while early prostate data and plans for market development in 2027 add incremental upside beyond current guidance.

Bears say

Axogen is vulnerable to slower growth because commercial coverage remains heterogeneous, with payer policies that can restrict nerve type, gap length, or anatomy and thus limit surgeon access and procedure volume. It also faces meaningful competitive risk from Integra LifeSciences, Stryker, and Baxter International, since broader adoption could weaken if differentiated off-the-shelf alternatives emerge despite Axogen’s current lead in biologically active processed human allografts. In addition, continued approval for portions of the Avance label depends on confirmatory studies, so delays, unfavorable results, or manufacturing non-compliance could narrow the label and jeopardize the durability of the franchise.

AxoGen (AXGN) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

AxoGen (AXGN) Analyst Forecast & Price Prediction

Get the latest AxoGen (AXGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AxoGen (AXGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 12 analysts, AxoGen (AXGN) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


AxoGen (AXGN) Analyst Forecast & Price Prediction

Get the latest AxoGen (AXGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AxoGen (AXGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AXGN stock data and trends